相似文献
1
How Similar Are Biosimilars? What Do Clinicians Need to Know About Biosimilar and Follow-On Insulins?
Clin Diabetes. 2017 Oct;35(4):209-216. doi: 10.2337/cd16-0072.
2
Biosimilar and Follow-on Insulin: The Ins, Outs, and Interchangeability.
J Pharm Technol. 2019 Feb;35(1):25-35. doi: 10.1177/8755122518802268. Epub 2018 Sep 28.
3
Biosimilar insulins are coming: the top 10 things you should know.
Postgrad Med. 2014 May;126(3):107-10. doi: 10.3810/pgm.2014.05.2760.
4
Biosimilar insulins are coming: what they are, what you need to know.
Curr Med Res Opin. 2014 Nov;30(11):2217-22. doi: 10.1185/03007995.2014.952718. Epub 2014 Aug 20.
5
The biosimilar insulin landscape: current developments.
Postgrad Med. 2014 Oct;126(6):81-92. doi: 10.3810/pgm.2014.10.2823.
6
The advent of biosimilars for the treatment of diabetes: current status and future directions.
Acta Diabetol. 2015 Jun;52(3):423-31. doi: 10.1007/s00592-015-0771-7. Epub 2015 May 20.
7
Biosimilars: what clinicians should know.
Blood. 2012 Dec 20;120(26):5111-7. doi: 10.1182/blood-2012-04-425744. Epub 2012 Oct 23.
8
A place for biosimilars in the changing multiple sclerosis treatment landscape.
Mult Scler Relat Disord. 2023 Sep;77:104841. doi: 10.1016/j.msard.2023.104841. Epub 2023 Jun 19.
9
Biosimilar therapeutics-what do we need to consider?
NDT Plus. 2009 Jan;2(Suppl_1):i27-i36. doi: 10.1093/ndtplus/sfn177.
10
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.
Rheumatol Int. 2016 May;36(5):613-25. doi: 10.1007/s00296-016-3444-0. Epub 2016 Feb 27.
引用本文的文献
1
Biosimilars: A Critical Review of Development, Regulatory Landscape, and Clinical Implications.
AAPS PharmSciTech. 2025 Jan 27;26(1):46. doi: 10.1208/s12249-025-03038-2.
2
Use of Biosimilars to Infliximab During Pregnancy in Women With Inflammatory Bowel Disease: Results From the Pregnancy in Inflammatory Bowel Disease and Neonatal Outcomes Study.
Clin Transl Gastroenterol. 2024 Dec 1;15(12):e00795. doi: 10.14309/ctg.0000000000000795.
3
Efficacy and Safety of Biosimilar Ranibizumab (OPTIMAB) Innovator Ranibizumab in Patients with Neovascular (Wet) Age-Related Macular Degeneration: A Double-Blind, Randomized, Multicenter, Phase III Study.
Clin Ophthalmol. 2024 Oct 29;18:3071-3081. doi: 10.2147/OPTH.S488866. eCollection 2024.
4
National Volume-Based Procurement (NVBP) exclusively for insulin: towards affordable access in China and beyond.
BMJ Glob Health. 2024 Jan 16;9(1):e014489. doi: 10.1136/bmjgh-2023-014489.
5
An Institutional Guide for Formulary Decisions of Biosimilars.
Hosp Pharm. 2023 Feb;58(1):38-48. doi: 10.1177/00185787221138007. Epub 2022 Nov 29.
6
A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's Ranibizumab with Lucentis in patients with neovascular age-related macular degeneration.
Indian J Ophthalmol. 2022 Aug;70(8):3008-3014. doi: 10.4103/ijo.IJO_2118_21.
7
The First Interchangeable Biosimilar Insulin: Insulin Glargine-yfgn.
J Diabetes Sci Technol. 2023 Mar;17(2):490-494. doi: 10.1177/19322968211067511. Epub 2021 Dec 31.
8
Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes.
Br J Ophthalmol. 2023 Mar;107(3):384-391. doi: 10.1136/bjophthalmol-2021-319637. Epub 2021 Oct 16.
9
MYL1501D Insulin Glargine: A Review in Diabetes Mellitus.
BioDrugs. 2020 Apr;34(2):245-251. doi: 10.1007/s40259-020-00418-x.
本文引用的文献
1
Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild-to-moderate renal impairment.
Diabetes Obes Metab. 2018 Dec;20(12):2860-2868. doi: 10.1111/dom.13470. Epub 2018 Aug 30.
2
Expenditures and Prices of Antihyperglycemic Medications in the United States: 2002-2013.
JAMA. 2016 Apr 5;315(13):1400-2. doi: 10.1001/jama.2016.0126.
3
Biosimilar Insulin and Costs: What Can We Expect?
J Diabetes Sci Technol. 2015 Sep 8;10(2):457-62. doi: 10.1177/1932296815605337.
4
Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies.
Diabetes Care. 2015 Dec;38(12):2226-33. doi: 10.2337/dc14-2623. Epub 2015 Aug 25.
5
What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs.
BMC Med. 2015 Jul 29;13:173. doi: 10.1186/s12916-015-0415-3.
6
The advent of biosimilars for the treatment of diabetes: current status and future directions.
Acta Diabetol. 2015 Jun;52(3):423-31. doi: 10.1007/s00592-015-0771-7. Epub 2015 May 20.
7
Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study.
Diabetes Obes Metab. 2015 Aug;17(8):726-33. doi: 10.1111/dom.12496. Epub 2015 Jun 23.
8
Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study).
Diabetes Obes Metab. 2015 Aug;17(8):734-41. doi: 10.1111/dom.12482. Epub 2015 May 31.
9
Biosimilar insulins: a European perspective.
Diabetes Obes Metab. 2015 May;17(5):445-51. doi: 10.1111/dom.12410. Epub 2014 Nov 27.
10
Patient Perspectives on Biosimilar Insulin.
J Diabetes Sci Technol. 2014 Jan;8(1):23-25. doi: 10.1177/1932296813515132. Epub 2014 Jan 1.
Zotero 插件